Development and psychometric properties of the Functional Assessment of Cancer Therapy–Cutaneous T-Cell Lymphoma (FACT-CTCL) instrument
British Journal of Dermatology · 23.12.2024 · 192 (1) · 78-84
DOI: 10.1093/bjd/ljae308 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift British Journal of Dermatology, online erschienen am 30.07.2024. Verfasst von Caroline Raymundo und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Washington School of Medicine, Seattle, WA, USA. Hauptthemen laut MEDLINE: Psychometrics, Quality of Life, Skin Neoplasms, Sezary Syndrome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Michael Piepkorn Endowed Chair in Dermatology Research, Merkel Cell Carcinoma Gift Fund.
Abstract (Originalsprache)
Background
Patients with mycosis fungoides (MF)/Sézary Syndrome (SS) can experience impacted health-related quality of life (HRQoL).
Objectives
To validate the CTCL-S, a novel subscale of the Functional Assessment of Cancer Therapy–General (FACT-G), in patients with MF/SS.
Methods
Qualitative interviews were conducted with expert clinicians and patients with MF/SS. Thematic analysis identified the most common concerns, and 19 items were selected. Patients with MF/SS were recruited from a single centre. FACT-G, CTCL-S (collectively ‘FACT-CTCL’), Skindex-29 and Visual Analogue Scale–Pruritis (VAS-itch) were administered. A subset repeated FACT-CTCL and VAS-itch after ≈2 weeks. Patient demographics and clinical characteristics were obtained via review of the electronic medical records. Psychometric properties were assessed. Internal consistency was estimated using Cronbach’s α. Convergent and discriminant validity were assessed by comparing CTCL-S with disease stage, age, VAS-itch, FACT-G and Skindex-29. Exploratory factor analysis (EFA) was used to preliminarily assess CTCL-S dimensionality. Test–retest repeatability was summarized using intraclass correlation coefficient (ICC), within-subject standard deviation and within-subject coefficient of variation.
Results
Seventy-two patients completed the initial survey, and 35 repeated the FACT-CTCL and VAS-itch after ≈2 weeks. Two-thirds were men; most were White (78%). The majority (85%) had MF, 15% had SS and 75% early (stage IA–IIA) and 25% advanced (≥ stage IIB) disease. Preliminary EFA found a single predominant factor, supporting a hypothesis of unidimensionality of the CTCL-S. Internal consistency of the CTCL-S was high, with α = 0.95 [95% confidence interval (CI) 0.93–0.96]. There was no significant change in CTCL-S average test–retest scores [ICC 0.93 (P = 0.63)]. CTCL-S was significantly lower in advanced vs. early-stage disease [median (interquartile range) 34 (26–48) vs. 59 (44–68), P < 0.001] and strongly correlated with VAS-itch [Spearman’s r (rs) –0.70, 95% CI –0.81 to –0.55], FACT-G (rs 0.77, 95% CI 0.65–0.85) and Skindex-29 (rs –0.90, 95% CI –0.94 to –0.84), supporting convergent validity. CTCL-S scores had little correlation with age (rs 0.19, 95% CI –0.05 to 0.41, P = 0.12), supporting discriminant validity.
Conclusions
The FACT-CTCL is a disease-specific instrument for assessing HRQoL with high reproducibility and good performance in a cohort of patients with MF/SS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of Washington School of Medicine, Seattle, WA, USA.
- Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
- Department of Health Policy and Management, University of North Carolina, Chapel Hill, NC, USA.
- Fred Hutchinson Cancer Center, Seattle, WA, USA.
- Northwestern University Department of Dermatology, Chicago, IL, USA.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA.
ORCID-Profile: David Cella, Mengyang Di, Christiane Querfeld
Förderung
- Michael Piepkorn Endowed Chair in Dermatology Research
- Merkel Cell Carcinoma Gift Fund
Zitieren
APA
Raymundo, C., Cella, D., Wagner, L. I., Hippe, D. S., Di, M., Guitart, J., Rosen, S. T., Querfeld, C., & Shinohara, M. M. (2024). Development and psychometric properties of the Functional Assessment of Cancer Therapy–Cutaneous T-Cell Lymphoma (FACT-CTCL) instrument. British Journal of Dermatology, 192(1), 78-84. https://doi.org/10.1093/bjd/ljae308
Vancouver
Raymundo C, Cella D, Wagner LI, Hippe DS, Di M, Guitart J, et al. Development and psychometric properties of the Functional Assessment of Cancer Therapy–Cutaneous T-Cell Lymphoma (FACT-CTCL) instrument. British Journal of Dermatology. 2024;192(1):78-84. doi:10.1093/bjd/ljae308
BibTeX
@article{Raymundo2024,
author = {Raymundo, Caroline and Cella, David and Wagner, Lynne I and Hippe, Daniel S and Di, Mengyang and Guitart, Joan and Rosen, Steven T and Querfeld, Christiane and Shinohara, Michi M},
title = {Development and psychometric properties of the Functional Assessment of Cancer Therapy–Cutaneous T-Cell Lymphoma (FACT-CTCL) instrument},
journal = {British Journal of Dermatology},
year = {2024},
volume = {192},
number = {1},
pages = {78--84},
doi = {10.1093/bjd/ljae308}
}
EUVIMED